HomeCompareOSMT vs GBDC

OSMT vs GBDC: Dividend Comparison 2026

OSMT yields 180.18% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OSMT wins by $45.26M in total portfolio value
10 years
OSMT
OSMT
● Live price
180.18%
Share price
$1.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$66.11M
Annual income
$31,604,469.02
Full OSMT calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — OSMT vs GBDC

📍 OSMT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSMTGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSMT + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSMT pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSMT
Annual income on $10K today (after 15% tax)
$15,315.32/yr
After 10yr DRIP, annual income (after tax)
$26,863,798.67/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, OSMT beats the other by $12,880,674.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSMT + GBDC for your $10,000?

OSMT: 50%GBDC: 50%
100% GBDC50/50100% OSMT
Portfolio after 10yr
$43.48M
Annual income
$24,027,601.43/yr
Blended yield
55.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

OSMT
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-8.0
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSMT buys
0
GBDC buys
0
No recent congressional trades found for OSMT or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSMTGBDC
Forward yield180.18%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$66.11M$20.85M
Annual income after 10y$31,604,469.02$16,450,733.83
Total dividends collected$61.93M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: OSMT vs GBDC ($10,000, DRIP)

YearOSMT PortfolioOSMT Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$28,718$18,018.02$12,492$1,791.70+$16.2KOSMT
2$79,087$48,359.04$16,527$3,160.58+$62.6KOSMT
3$209,088$124,464.74$23,588$5,904.90+$185.5KOSMT
4$531,253$307,528.35$37,141$11,901.65+$494.1KOSMT
5$1,298,693$730,252.50$66,205$26,463.38+$1.23MOSMT
6$3,057,980$1,668,378.52$137,452$66,612.65+$2.92MOSMT
7$6,943,500$3,671,461.50$342,372$195,298.53+$6.60MOSMT
8$15,220,649$7,791,104.22$1,053,292$686,954.33+$14.17MOSMT
9$32,247,458$15,961,362.93$4,111,439$2,984,416.95+$28.14MOSMT
10$66,109,249$31,604,469.02$20,849,974$16,450,733.83+$45.26MOSMT

OSMT vs GBDC: Complete Analysis 2026

OSMTStock

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Full OSMT Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this OSMT vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSMT vs SCHDOSMT vs JEPIOSMT vs OOSMT vs KOOSMT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.